Submit to Cancers Review for Cancers Propose a Special Issue

Journal Menu

Journal Browser

Special Issue "Global Management of Sarcoma Data: Is Real-Time Predictive Analytics on the Horizon?"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Informatics and Big Data".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 5629

Share This Special Issue

Special Issue Editor

Prof. Dr. Bruno Fuchs

E-Mail Website
Guest Editor

Sarcoma Service, University of Lucerne, CH-6004 Luzern, Switzerland
Interests: sarcoma surgery; sarcoma MDT; quality indicators; VBHC

Special Issue Information

Dear Colleagues,

Sarcomas belong to the rare diseases, there are some 150 molecularly defined biological subtypes, and its treatment is highly complex and transdisciplinary. The development of novel therapies has been stagnating over years for numerous complex reasons. Although it is accepted that only the interplay of several disciplines may render successful treatment results in sarcoma patients, data are usually still mono-disciplinarily reported, and there is no global approach for longitudinal prospective acquisition of structured data on quality. The successful introduction of the “Sarculator” and “PerSarc” -though still imperfect tools- has demonstrated the urge how clinicians starve for outcome prediction tools to incorporate into their strategic treatment decisions. Whereas real-time outcome prediction for sarcoma patients is the defined goal, we have to define the approach how to get there on a global level considering all possible aspects.

A first step includes the establishment of an overview what is available to then possibly orchestrate on the global level, and to outline the opportunities.

Herewith, we aim for a current global representation of sarcoma registries available within the existing sarcoma networks with detailed overview how they work. Further, we want to consider the novel opportunities of digital transformation and challenges of international data exchange and analytics.

Prof. Dr. Bruno Fuchs
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

sarcoma
registry/data bases
data harmonization and exchange
global collaboration
digital transformation
predictive outcome analytics
prognosis & prognostic research
prognostic and predictive models
predictive analytics & machine learning

Published Papers (5 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

21 pages, 2132 KiB

Open AccessArticle

Enhancing Healthcare for Sarcoma Patients: Lessons from a Diagnostic Pathway Efficiency Analysis

Maria Elyes

Philip Heesen

Georg Schelling

Beata Bode-Lesniewska

Gabriela Studer

and

Bruno Fuchs

Cancers 2023, 15(19), 4892; https://doi.org/10.3390/cancers15194892 - 09 Oct 2023

Viewed by 552

Abstract

Sarcomas, rare and with lower survival rates than common tumors, offer insights into healthcare efficiency via the analysis of the total interval of the diagnostic pathway, combining the patient interval (time between the first symptom and visit with a physician) and diagnostic interval (time between first physician visit and histological diagnosis). Switzerland’s healthcare system, Europe’s costliest, lacks research on treating rare conditions, like mesenchymal tumors. This study examines the total interval of the diagnostic pathway for optimization strategies. Analyzing a dataset of 1028 patients presented from 2018 to 2021 to the Swiss Sarcoma Board (MDT/SB-SSN), this retrospective analysis delves into bone sarcoma (BS), soft-tissue sarcoma (STS), and their benign counterparts. Demographic and treatment data were extracted from medical records. The patient interval accounted for the largest proportion of the total interval and secondary care interval for the largest proportion of the diagnostic interval. Age, grade, and localization could be elicited as influencing factors of the length of different components of the total interval. An increasing age and tumor size, as well as the axial localization, could be elicited as factors increasing the probability of sarcoma. The patient and secondary care interval (SCI) offer the greatest potential for optimization, with SCI being the bottleneck of the diagnostic interval. New organizational structures for care work-ups are needed, such as integrated practice units (IPU) as integral part of value-based healthcare (VBHC). Full article

(This article belongs to the Special Issue Global Management of Sarcoma Data: Is Real-Time Predictive Analytics on the Horizon?)

► Show Figures

Figure 1

17 pages, 3895 KiB

Open AccessArticle

Unlocking the Power of Benchmarking: Real-World-Time Data Analysis for Enhanced Sarcoma Patient Outcomes

Beata Bode-Lesniewska

Mario F. Scaglioni

Pietro Giovanoli

Philip Heesen

and on behalf of the SwissSarcomaNetwork

Cancers 2023, 15(17), 4395; https://doi.org/10.3390/cancers15174395 - 02 Sep 2023

Cited by 2 | Viewed by 750

Abstract

Benchmarking is crucial for healthcare providers to enhance quality and efficiency, notably for complex conditions like sarcomas. Multidisciplinary teams/sarcoma boards (MDT/SBs) are vital in sarcoma management, but differences in their processes can affect patient outcomes and treatment costs, despite adherence to international guidelines. To address this issue, this study aimed to compare two MDT/SBs and establish an interoperable digital platform, Sarconnector^®, for real-time-world data assessment and automated analysis. The study included 983 patients, 46.0% of whom female, with a median age of 58 years, and 4.5% of patients presented with metastasis at diagnosis. Differences were observed in the number of first-time presentations, follow-up presentations, primary sarcomas, biopsies and chemotherapy indications between the two MDT/SB. The results highlight the importance of benchmarking and utilizing a harmonized data approach, such as the RWT approach provided by the Sarconnector^®, to standardize and evaluate quality and cost metrics. By identifying areas of improvement and making data-driven decisions on the meta-level, healthcare providers can optimize resources and improve patient outcomes. In conclusion, benchmarking with the RWT harmonized data approach provided by the Sarconnector^® can help healthcare providers improve the overall effectiveness of the healthcare system and achieve better outcomes for their patients in terms of both outcomes and costs. Full article

(This article belongs to the Special Issue Global Management of Sarcoma Data: Is Real-Time Predictive Analytics on the Horizon?)

► Show Figures

Figure 1

11 pages, 1972 KiB

Open AccessArticle

How Is the Spectrum of Sarcoma Surgery Assessed?

Carlo Theus-Steinmann

and

Cancers 2023, 15(4), 1305; https://doi.org/10.3390/cancers15041305 - 18 Feb 2023

Cited by 1 | Viewed by 959

Abstract

Purpose: To meet the challenges of the precision medicine era, quality assessment of shared sarcoma care becomes pivotal. The MDT approach is the most important parameter for a successful outcome. Of all MDT disciplines, surgery is the key step to rendering sarcoma patients disease free; therefore, defining its spectrum is critical. To the best of the authors’ knowledge, a comprehensive interoperable digital platform to assess the scope of sarcoma surgery in its full complexity is lacking. Methods: An interoperable digital platform on sarcoma surgery has been created to assess the clinical exposure, tumor characteristics, and surgical settings and techniques applied for both resections and reconstructions of sarcomas. Results: The surgical exposure of an individual surgeon over time served as a pilot. Over the study period of 10 years, there were 723 sarcoma board/MDT meetings discussing 3130 patients. A total of 1094 patients underwent 1250 surgical interventions on mesenchymal tumors by one single sarcoma surgeon. These included 615 deep soft tissue tumors (197 benign, 102 intermediate, 281 malignant, 27 simulator, 7 metastasis, 1 blood); 116 superficial soft tissue tumors (45 benign, 12 intermediate, 40 malignant, 18 simulator, 1 blood); and 519 bone tumors (129 benign, 112 intermediate, 182 malignant, 18 simulator, 46 metastasis, 14 blood, and 18 sequelae of first treatment). Detailed types of resections and reconstructions were analyzed. Conclusions: An interoperable digital data platform on sarcoma surgery with transparent real-time descriptive analytics is feasible and enables large-scale definition of the spectrum of sarcoma surgery to meet the challenges of sarcoma precision care in the future. Full article

(This article belongs to the Special Issue Global Management of Sarcoma Data: Is Real-Time Predictive Analytics on the Horizon?)

► Show Figures

Figure 1

12 pages, 1724 KiB

Open AccessFeature PaperArticle

Quality of Sarcoma Care: Longitudinal Real-Time Assessment and Evidence Analytics of Quality Indicators

and

Cancers 2023, 15(1), 47; https://doi.org/10.3390/cancers15010047 - 22 Dec 2022

Cited by 3 | Viewed by 1641

Abstract

Sarcomas represent a large group of rare to very rare diseases, requiring complex management with a transdisciplinary approach. Overall progress has been hampered because of discipline, institution and network fragmentation, and there is no global data harmonization or quality standards. To report on and improve quality, a common definition of quality indicators (QIs) of sarcoma care as well as the capacity to assess longitudinal real-time data is required. An international advisory board of world-renowned sarcoma experts defined six categories of QIs, totaling more than 80 quality indicators. An interoperable (web-based) digital platform was then created combining the management of the weekly sarcoma board meeting with the sarcoma registry and incorporating patient-reported outcome measures (PROMs) into the routine follow-up care to assess the entire care cycle of the patient. The QIs were then programmed into the digital platform for real-time analysis and visualization. The definition of standardized QIs covering all physician- (diagnostics and therapeutics), patient- (PROMS/PREMS), and cost-based aspects in combination with their real-time assessment over the entire sarcoma care cycle can be realized. Standardized QIs as well as their real-time assessment and data visualization are critical to improving the quality of sarcoma care. By enabling predictive modelling and introducing VBHC, precision health care for a complex disease is on the horizon. Full article

(This article belongs to the Special Issue Global Management of Sarcoma Data: Is Real-Time Predictive Analytics on the Horizon?)

► Show Figures

Figure 1

Review

Jump to: Research

17 pages, 872 KiB

Open AccessReview

Establishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS)

and

Stefanie Hecker-Nolting

Cancers 2023, 15(5), 1520; https://doi.org/10.3390/cancers15051520 - 28 Feb 2023

Cited by 2 | Viewed by 975

Abstract

Introduction: Osteosarcoma treatment has benefitted greatly from collaborative research. This paper describes the history and accomplishments of the Cooperative Osteosarcoma Study Group (COSS), mainly dedicated to clinical questions, as well as remaining challenges. Materials and Methods: Narrative review of over four decades of uninterrupted collaboration within the multi-national German–Austrian–Swiss COSS group. Results: Since its very first prospective osteosarcoma trial starting in 1977, COSS has continuously been able to provide high-level evidence on various tumor- and treatment-related questions. This includes both the cohort of patients enrolled into prospective trials as well as those patients excluded from them for various reasons, followed in a prospective registry. Well over one hundred disease-related publications attest to the group’s impact on the field. Despite these accomplishments, challenging problems remain. Discussion: Collaborative research within a multi-national study group resulted in better definitions of important aspects of the most common bone tumor, osteosarcoma, and its treatments. Important challenges continue to persist. Full article

(This article belongs to the Special Issue Global Management of Sarcoma Data: Is Real-Time Predictive Analytics on the Horizon?)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Global Management of Sarcoma Data: Is Real-Time Predictive Analytics on the Horizon?"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (5 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI